Skip to main content
Clinical Trials/NCT05422963
NCT05422963
Unknown
Not Applicable

Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai

Ruijin Hospital1 site in 1 country1,000 target enrollmentJune 10, 2022
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
Ruijin Hospital
Enrollment
1000
Locations
1
Primary Endpoint
28-day mortality
Last Updated
3 years ago

Overview

Brief Summary

This study is to clarify the clinical characteristics of severe and critical COVID-19 from March 1st ,2022 to June 9th, 2022 in Shanghai and to explore the relationship between the characteristics and prognosis in these patients.

Detailed Description

1. To Describe the clinical characteristics of severe and critical COVID-19. 2. To analyze the relationship between the clinical characteristics and their clinical prognosis; 3. To analyze the relationship between clinical intervention and their clinical prognosis.

Registry
clinicaltrials.gov
Start Date
June 10, 2022
End Date
June 10, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • severe and critical covid-19 patients who met the "Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
  • admission time more than 24 hours

Exclusion Criteria

  • admission time less than 24 hours

Outcomes

Primary Outcomes

28-day mortality

Time Frame: one year

28-day mortality of severe and critical COVID-19

Secondary Outcomes

  • 60-day mortality(one year)
  • the percentage of organ failure(one year)
  • ICU length of stay(one year)
  • time for virus to turn negative(one year)
  • The overall description(one year)

Study Sites (1)

Loading locations...

Similar Trials